Zheng, Ya
Ching, Jessica
Cheng, Chung Wah
Lam, Wai Ching
Chan, Kam Leung
Zhang, Xuan
Lam, Pui Yan
Wu, Xing Yao
Zhong, Linda L. D.
Cao, Pei Hua
Lo, Cho Wing
Cheong, Pui Kuan
Lin, Zhixiu
Koh, Matthew
Wu, Justin
Bian, Zhao Xiang http://orcid.org/0000-0001-6206-1958
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
https://doi.org/10.1186/s13020-021-00530-2
Funding for this research was provided by:
The Innovative Technology Commission of HKSAR, China (ITS-148-14FP)
Article History
Received: 7 October 2021
Accepted: 31 October 2021
First Online: 13 November 2021
Declarations
:
: The study has been approved by the Hong Kong Baptist University Research Ethics Committee (HASC/16-17/C01) and Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee (2016.718-T). Clinical Trial Certificate has been awarded by the Department of Health of Hong Kong Special Administrative Region, China (CTMT-00007). The study is also registered in the ClinicalTrials.gov (NCT03457324). All protocol amendment have been approved by the above ethics committees. Before each participant being enrolled into the study for efficacy and safety assessment and biological specimen (Urine, Blood and feces) collection, written informed consent to participate will be gotten from all participants after clear explanation about the study (Additional file InternalRef removed).
: All authors have approved to submit the manuscript.
: The authors declare that they have no competing interest.